Ten Years On. The Impact of Biologics on the Practice of Dermatology

Dermatologic Clinics

Volumn 33, Issue 1, 2015, Pages 111-125

  Leonardi, Craig L ^a   Romiti, Ricardo ^b   Tebbey, Paul W ^c  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c International Psoriasis Council   (United States)

Author keywords

Biologics; Clinical trials; Cytokines; Efficacy; Monoclonal antibodies; Psoriasis; Quality of life; Safety

Indexed keywords

ADALIMUMAB; ALEFACEPT; BIOLOGICAL PRODUCT; BRODALUMAB; CERTOLIZUMAB PEGOL; EFALIZUMAB; ETANERCEPT; GUSELKUMAB; INFLIXIMAB; IXEKIZUMAB; METHOTREXATE; PLACEBO; SECUKINUMAB; TILDRAKIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ABNORMAL LABORATORY RESULT; ADENOMA; ALLERGY; ANAPHYLAXIS; APLASTIC ANEMIA; ARTHRALGIA; AUTOIMMUNE HEPATITIS; BACKACHE; BACTERIAL ARTHRITIS; BRONCHITIS; CANDIDIASIS; CARDIOVASCULAR DISEASE; CELLULITIS; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOPENIA; DACTYLITIS; DEMYELINATING DISEASE; DERMATOLOGIST; DISEASE EXACERBATION; DIVERTICULITIS; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG RECALL; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; ENTHESITIS; FASCIITIS; HEADACHE; HEART FAILURE; HEMOLYTIC ANEMIA; HEPATITIS B; HERPES ZOSTER; HUMAN; HYPERSENSITIVITY; IMMUNE DEFICIENCY; INFECTION; INFUSION RELATED REACTION; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LIVER TOXICITY; LONG TERM CARE; LUPUS LIKE SYNDROME; LYMPHEDEMA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NEUTROPENIA; NON MELANOMA SKIN CANCER; OUTCOME ASSESSMENT; OVARY CYST; PANCYTOPENIA; PATHOPHYSIOLOGY; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOTHERAPY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; POSTMARKETING SURVEILLANCE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; SINUSITIS; SYSTEMIC MYCOSIS; TH17 CELL; THROMBOCYTOPENIA; TINEA PEDIS; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRUS MENINGITIS; ANTAGONISTS AND INHIBITORS; BIOLOGICAL THERAPY; DERMATOLOGY; DRUG EFFECTS; T LYMPHOCYTE; TIME; TRENDS;

ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; DERMATOLOGY; HUMANS; PSORIASIS; QUALITY OF LIFE; T-LYMPHOCYTES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84911466503     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2014.09.009     Document Type: Review

References (79)

1. Griffiths C.E., Christophers E., Barker J.N., et al. Aclassification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007, 156:258-262.
2. Menter A., Griffiths C.E. Current and future management of psoriasis. Lancet 2007, 370:272-284.
3. Rapp S.R., Feldman S.R., Exum M.L., et al. Psoriasis causes as much disability as other major medical diseases. JAm Acad Dermatol 1999, 41:401-407.
4. Menter A., Griffiths C.E., Tebbey P.W., et al. Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. JEur Acad Dermatol Venereol 2010, 24:1371-1377.
5. Mehta N.N., Yu Y., Pinnelas R., et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011, 124(8):775.e1-775.e6.
6. Neimann A.L., Shin D.B., Wang X., et al. Prevalence of cardiovascular risk factors in patients with psoriasis. JAm Acad Dermatol 2006, 55:829-835.
7. Sterry W., Strober B.E., Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007, 157:649-655.
8. Kaye J.A., Li L., Jick S.S. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008, 159:895-902.
9. Ogdie A., Haynes K., Troxel A.B., et al. Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. Ann Rheum Dis 2014, 73(1):149-153.
10. Griffiths C.E., Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet 2007, 370:263-271.
11. Nestle F.O., Kaplan D.H., Barker J.N. Psoriasis. NEngl J Med 2009, 361:496-509.
12. Menter A., Gottlieb A., Feldman S.R., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. JAm Acad Dermatol 2008, 58:826-850.
13. Horn E.J., Fox K.M., Patel V., et al. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. JAm Acad Dermatol 2007, 57(6):957-962.
14. Armstrong A.W., Robertson A.D., Wu J., et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol 2013, 149(10):1180-1185.
15. Silveira M.S., do N., de Camargo I.A., et al. Adherence to guidelines in the use of biological agents to treat psoriasis in Brazil. BMJ Open 2014, 4:e004179.
16. Kanitakis J., Butnaru A.C., Claudy A. Novel biological immunotherapies for psoriasis. Expert Opin Investig Drugs 2003, 12(7):1111-1121.
17. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
18. Strober B.E., Armour K., Romiti R., et al. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. JAm Acad Dermatol 2012, 66(2):317-322.
19. Enbrel (etanercept) [package insert]. Thousand Oaks, CA: Immunex Corp; 2013.
20. Remicade (infliximab) [package insert]. Horsham, PA: Janssen Biotech, Inc; 2013.
21. Humira (adalimumab) [package insert]. North Chicago, IL: AbbVie Inc; 2013.
22. Stelara (ustekinumab) [package insert]. Horsham, PA: Janssen Biotech, Inc; 2012.
23. Furst D.E., Wallis R., Broder M., et al. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006, 36:159-167.
24. Pariser D.M. The age of biologics: we've never seen anything like this. Manag Care 2003, 12(Suppl 5):1.
25. Amevive (alefacept) [package insert]. Deerfield, IL: Astellas Pharma US, Inc; 2011.
26. Ellis C., Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. NEngl J Med 2001, 345:248-255.
27. Gordon K.B., Langley R.G. Remittive effects of intramuscular alefacept in psoriasis. JDrugs Dermatol 2003, 2(6):624-628.
28. Haider A.S., Lowes M.A., Gardner H., et al. Novel insight into the agonistic mechanism of alefacept invivo: differentially expressed genes may serve as biomarkers of response in psoriasis patients. JImmunol 2007, 178(11):7442-7449.
29. Raptiva (efalizumab) [package insert]. South San Francisco, CA: Genentech, Inc; 2009.
30. Yawalkar N., Karlen S., Hunger R., et al. Expression of interleukin-12 is increased in psoriatic skin. JInvest Dermatol 1998, 111(6):1053-1057.
31. Lowes M.A., Kikuchi T., Fuentes-Duculan J., et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and TH17 T cells. JInvest Dermatol 2008, 128(5):1207-1211.
32. Leonardi C.L., Kimball A.B., Papp K.A., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371:1665-1674.
33. Papp K.A., Langley R.G., Lebwohl M., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008, 371:1675-1684.
34. Villanova F., Di Meglio P., Nestle F.O. Biomarkers in psoriasis and psoriatic arthritis. Ann Rheum Dis 2013, 72(Suppl 2):ii104-ii110.
35. Reich K., Burden A.D., Eaton J.N., et al. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol 2012, 166(1):179-188.
36. Leonardi C.L., Powers J.L., Matheson R.T., Etanercept Psoriasis Study Group, et al. Etanercept as monotherapy in patients with psoriasis. NEngl J Med 2003, 349(21):2014-2022.
37. Malaviya R., Sun Y., Tan J.K., et al. Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis. JDrugs Dermatol 2006, 5(9):890-893.
38. Reich K., Nestle F.O., Papp K., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005, 366(9494):1367-1374.
39. Menter A., Feldman S.R., Weinstein G.D., et al. Arandomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. JAm Acad Dermatol 2007, 56(1):31.e1-31.e15.
40. Kimball A., Leonardi C., Stahle M., et al. Demography, baseline disease characteristics, and treatment history of patients with psoriasis enrolled in a multicenter, prospective, disease-based registry (PSOLAR). Br J Dermatol 2014, 10.1111/bjd.13013.
41. Gordon K.B., Langley R.G., Leonardi C., et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. JAm Acad Dermatol 2006, 55(4):598-606.
42. Menter A., Tyring S.K., Gordon K., et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. JAm Acad Dermatol 2008, 58(1):106-115.
43. Reich K., Ortonne J.P., Gottlieb A.B., et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol 2012, 167(1):180-190.
44. Romero-Mate A., Garcia-Donoso C., Cordoba-Guijarro S. Efficacy and safety of etanercept on psoriasis/psoriatic arthritis: an updated review. Am J Clin Dermatol 2007, 8:143-155.
45. Papousatki M., Talamonti M., Giunta A., et al. The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab. Dermatology 2010, 221(Suppl 1):43-47.
46. Gordon K., Papp K., Poulin Y., et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years; results from an open-label extension study for patients from REVEAL. JAm Acad Dermatol 2011, 66:241-251.
47. Burden A.D., Warren R.B., Kleyn C.E., et al. The British Association of Dermatologists' Biologic Interventions Register (BADBIR) design, methodology, and objectives. Br J Dermatol 2012, 166:545-554.
48. van Lümig P.P., Driessen R.J., Berends M.A., et al. Safety of treatment with biologics for psoriasis in daily practice: 5-year data. JEur Acad Dermatol Venereol 2012, 26(3):283-291.
49. Kimball A.B., Papp K.A., Wasfi Y., et al. Long-term efficacy of ustekinumab in patients with moderate to severe psoriasis treated for up to 5 years in the PHOENIX 1 study. JEur Acad Dermatol Venereol 2013, 27(12):1535-1545.
50. Wu J.J., Poon K.Y., Channual J.C., et al. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 2012, 148(11):1244-1250.
51. Papp K.A., Poulin Y., Bissonette R., et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. JAm Acad Dermatol 2012, 66:e33-e45.
52. Torii H., Nakagawa H. Infliximab monotherapy in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis. A randomized, double- blind, placebo controlled multicenter trial. JDermatol Sci 2010, 59:40-49.
53. Mease P.J., Menter M.A. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. JAm Acad Dermatol 2006, 54(4):685-704.
54. Choi J., Koo J.Y. Quality of life issues in psoriasis. JAm Acad Dermatol 2003, 49(Suppl 2):S57-S61.
55. Basra M.K., Hussain S. Application of the dermatology life quality index in clinical trials of biologics for psoriasis. Chin J Integr Med 2012, 18(3):179-185.
56. Finlay A.Y., Khan G.K., Luscombe D.K., et al. Validation of sickness impact profile and psoriasis disability index in psoriasis. Br J Dermatol 1990, 123:751-756.
57. Bhutani T., Patel T., Koo B., et al. Aprospective, interventional assessment of psoriasis quality of life using a nonskin-specific validated instrument that allows comparison with other major medical conditions. JAm Acad Dermatol 2013, 69:e79-e88.
58. Zachariae R., Zachariae H., Blomqvist K., et al. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol 2002, 146:1006-1016.
59. Stern R.S., Nijsten T., Feldman S.R., et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. JInvestig Dermatol Symp Proc 2004, 9:136-139.
60. Mahler R., Jackson C., Ijacu H. The burden of psoriasis and barriers to satisfactory care: results from a Canadian patient survey. JCutan Med Surg 2009, 13(6):283-293.
61. Panigalli S., Coccarielli D., Germi L., et al. Non-randomized pilot study on the evaluation of the quality of life and psychosocial stress before and after systemic therapy in patients affected by moderate to severe psoriasis. JBiol Regul Homeost Agents 2009, 23(2):111-117.
62. Callis Duffin K., Yeung H., Takeshita J., et al. Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. Br J Dermatol 2014, 170(3):672-680.
63. Katugampola R.P., Lewis V.J., Finlay A.Y. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol 2007, 156:945-950.
64. Revicki D.A., Willian M.K., Menter A., et al. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology 2008, 216(3):260-270.
65. Strand V., Sharp V., Koenig A.S., et al. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis 2012, 71(7):1143-1150.
66. Tyring S., Gottlieb A., Papp K., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet 2006, 367:29-35.
67. Langley R.G., Feldman S.R., Han C., et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. JAm Acad Dermatol 2010, 63(3):457-465.
68. Tsai T.F., Song M., Shen Y.K., PEARL Investigators, et al. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial. JDrugs Dermatol 2012, 11(8):943-949.
69. Saad A.A., Ashcroft D.M., Watson K.D., et al. Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. Arthritis Care Res 2010, 62(3):345-353.
70. van den Reek J.M., Zweegers J., Kievit W., et al. 'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care - results from the BioCAPTURE network. Br J Dermatol 2014, [Epub ahead of print].
71. Papp K.A., Langley R.G., Sigurgeirsson B., et al. Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013, 168:412-421.
72. Papp K.A., Leonardi C., Menter A., et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. NEngl J Med 2012, 366(13):1181-1189.
73. Leonardi C., Matheson R., Zachariae C., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. NEngl J Med 2012, 366(13):1190-1199.
74. Harper E.G., Guo C., Rizzo H., et al. TH17 cytokines stimulate CCL20 expression in keratinocytes invitro and invivo: implications for psoriasis pathogenesis. JInvest Dermatol 2009, 129:2175-2183.
75. Langley R, Reich K, Griffiths C, etal. Secukinumab compared with placebo and etanercept: a head-to-head comparison of two biologics in a phase 3 study of moderate-to-severe plaque psoriasis (FIXTURE) [poster]. Presented at the 22nd European Academy of Dermatology and Venereology Congress. Istanbul, Turkey, October 26, 2013.
76. Amgen and AstraZeneca (THOUSAND OAKS, Calif. and LONDON, UK.) Positive results from phase 3 study Of brodalumab (AMG 827) in patients with moderate-to-severe plaque psoriasis study evaluating novel investigational IL-17 receptor antibody meets all primary and secondary endpoints, 2014/PRNewswire/Press Release.
77. Sofen H., Smith S., Matheson R.T., et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. JAllergy Clin Immunol 2014, 133:1032-1040.
78. Leonardi C.L., Gordon K.B. New and emerging therapies in psoriasis. Semin Cutan Med Surg 2014, 33(2 Suppl 2):S37-S41.
79. Ryan C., Leonardi C.L., Krueger J.G., et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011, 306(8):864-871.